Frankfurt - Delayed Quote EUR
Viking Therapeutics, Inc. (1VT.F)
As of 9:21 AM GMT+2. Market Open.
Research Analysis
Earnings Per Share
Analyst Price Targets
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 11 |
| Avg. Estimate | -0.21 | -0.22 | -0.81 | -1.08 |
| Low Estimate | -0.23 | -0.24 | -0.86 | -1.99 |
| High Estimate | -0.2 | -0.2 | -0.77 | -0.64 |
| Year Ago EPS | -0.13 | -0.15 | -0.54 | -0.81 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 11 |
| Avg. Estimate | -- | -- | -- | 80k |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 900k |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2020 | 12/31/2020 | 3/31/2021 | 6/30/2021 |
|---|---|---|---|---|
| EPS Est. | -0.15 | -0.15 | -0.17 | -0.2 |
| EPS Actual | -0.13 | -0.15 | -0.19 | -0.2 |
| Difference | 0.02 | 0 | -0.02 | 0 |
| Surprise % | 13.30% | 0.00% | -11.80% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Current Estimate | -0.21 | -0.22 | -0.81 | -1.08 |
| 7 Days Ago | -0.21 | -0.22 | -0.81 | -1.08 |
| 30 Days Ago | -0.21 | -0.22 | -0.81 | -1.08 |
| 60 Days Ago | -0.21 | -0.23 | -0.83 | -1.08 |
| 90 Days Ago | -0.21 | -0.23 | -0.83 | -1.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | 1VT.F | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -61.50% | -- | -- | 3.60% |
| Next Qtr. | -46.70% | -- | -- | 7.90% |
| Current Year | -50.00% | -- | -- | 2.50% |
| Next Year | -33.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 40.00% | -- | -- | 11.87% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/9/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 9/25/2024 |
| Reiterates | Morgan Stanley: Overweight to Overweight | 9/12/2024 |
| Initiated | JP Morgan: Overweight | 9/11/2024 |
| Maintains | Raymond James: Strong Buy to Strong Buy | 7/25/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/25/2024 |
Related Tickers
430.F Terns Pharmaceuticals Inc
6.55
-1.50%
20D0.F Cidara Therapeutics, Inc.
10.20
0.00%
J7Z.F Jazz Pharmaceuticals plc
103.50
-0.72%
HTD.MU Corcept Therapeutics Inc
45.34
0.00%
RGO.HA Regeneron Pharmaceuticals Inc
892.20
-0.51%
BO1.MU BioCryst Pharmaceuticals Inc
6.85
-1.27%
LSRM.MU CEL-SCI Corp
0.8690
0.00%
LSRM.BE CEL-SCI Corp
0.8100
+0.06%
0RK.F Exscientia plc
4.6000
-2.13%
ISI.SG Ionis Pharmaceuticals Inc
35.72
-0.25%